Frano Vučković
Research Subjects
Research Interests
Frano Vučković has a total of 413 co-authors. Here are the top co-authors by number of shared publications:
- Gordan Lauc
Genos Ltd., 10000 Zagreb, Croatia
30 shared publications - Irena Trbojević-Akmačić
Genos Glycoscience Research Laboratory, Zagreb, Croatia
13 shared publications - Yurii Sergeevich Aulchenko
MSU Institute for Artificial Intelligence, Lomonosov Moscow State University, Moscow, Russia
8 shared publications - Maja Pučić-Baković
Genos Glycoscience Research Laboratory
7 shared publications - Massimo Allegri
Centre Lémanique de Neuromodulation et Thérapie de la Douleur, Ensemble Hospitalier de la Côte (EHC), 1110 Morges, Switzerland
7 shared publications - Olga Gornik
Department of Biochemistry and Molecular Biology, Faculty of Pharmacy and Biochemistry, University of Zagreb, 10000 Zagreb, Croatia
7 shared publications
Latest Publications
- Open Access
- 23 September 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (10) , 2150
Plasma IgG N-Glycosylation as a Novel Biomarker of Disease Severity and Prognosis in Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Background: Diffuse large B-cell lymphoma (DLBCL) is a biologically heterogeneous lymphoma with variable clinical outcomes despite established molecular and clinical prognostic models. Immunoglobulin G (IgG) N-glycosylation regulates antibody effector functions and reflects systemic immune status, but plasma IgG N-glycosylation has not previously been systematically investigated in DLBCL. We evaluated whether plasma IgG N-glycosylation is altered in DLBCL and examined its associations with molecular subtype, established prognostic indices, and clinical outcomes. Methods: Plasma samples were obtained from 54 treatment-naïve patients with pathologically confirmed DLBCL, not otherwise specified (NOS), and 54 age- and sex-matched healthy controls. IgG N-glycans were analyzed using capillary gel electrophoresis with laser-induced fluorescence (CGE-LIF), resolving 27 glycan peaks that were summarized into six derived glycosylation traits: agalactosylation (G0), monogalactosylation (G1), digalactosylation (G2), sialylation (S), bisecting N-acetylglucosamine (B), and core fucosylation (CF). Associations with disease status, cell-of-origin subtype, prognostic indices (International Prognostic Index (IPI), Age-Adjusted International Prognostic Index (aaIPI), revised International Prognostic Index (R-IPI), National Comprehensive Cancer Network International Prognostic index (NCCN-IPI), Central Nervous System International Prognostic Index (CNS-IPI) and inflammation-based cumulative prognostic score system (ICPS)) progression-free survival (PFS), overall survival (OS), and relapse were assessed using multivariable regression and Cox proportional hazards models adjusted for age and sex. Multiple testing was controlled using the Benjamini–Hochberg false discovery rate. Results: Compared with healthy controls, patients with DLBCL, NOS exhibited significantly increased agalactosylation and decreased digalactosylation and sialylation, consistent with a pro-inflammatory IgG glycosylation profile. The non-germinal center B-cell-like (non-GCB) subtype showed significantly lower monogalactosylation than germinal center B-cell like (GCB) DLBCL. Across multiple established prognostic indices, increasing clinical risk was consistently associated with increased agalactosylation and reduced digalactosylation. During follow-up, 20 patients (37%) relapsed, and 21 (39%) died. Increased agalactosylation was independently associated with shorter PFS, whereas reduced sialylation predicted both inferior PFS and an increased risk of relapse. Conclusions: Plasma IgG N-glycosylation is profoundly altered in DLBCL, NOS and is associated with molecular subtype, established prognostic indices, and clinically relevant outcomes. These findings identify plasma IgG N-glycosylation as a promising minimally invasive biomarker that reflects disease biology and provides prognostic information beyond conventional clinical risk models. Given the exploratory nature and modest size of this cohort, these findings should be considered hypothesis-generating and require validation in larger prospective cohorts.
- 23 September 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (10) , 2150
Open AccessPlasma IgG N-Glycosylation as a Novel Biomarker of Disease Severity and Prognosis in Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Background: Diffuse large B-cell lymphoma (DLBCL) is a biologically heterogeneous lymphoma with variable clinical outcomes despite established molecular and clinical prognostic models. Immunoglobulin G (IgG) N-glycosylation regulates antibody effector functions and reflects systemic immune status, but plasma IgG N-glycosylation has not previously been systematically investigated in DLBCL. We evaluated whether plasma IgG N-glycosylation is altered in DLBCL and examined its associations with molecular subtype, established prognostic indices, and clinical outcomes. Methods: Plasma samples were obtained from 54 treatment-naïve patients with pathologically confirmed DLBCL, not otherwise specified (NOS), and 54 age- and sex-matched healthy controls. IgG N-glycans were analyzed using capillary gel electrophoresis with laser-induced fluorescence (CGE-LIF), resolving 27 glycan peaks that were summarized into six derived glycosylation traits: agalactosylation (G0), monogalactosylation (G1), digalactosylation (G2), sialylation (S), bisecting N-acetylglucosamine (B), and core fucosylation (CF). Associations with disease status, cell-of-origin subtype, prognostic indices (International Prognostic Index (IPI), Age-Adjusted International Prognostic Index (aaIPI), revised International Prognostic Index (R-IPI), National Comprehensive Cancer Network International Prognostic index (NCCN-IPI), Central Nervous System International Prognostic Index (CNS-IPI) and inflammation-based cumulative prognostic score system (ICPS)) progression-free survival (PFS), overall survival (OS), and relapse were assessed using multivariable regression and Cox proportional hazards models adjusted for age and sex. Multiple testing was controlled using the Benjamini–Hochberg false discovery rate. Results: Compared with healthy controls, patients with DLBCL, NOS exhibited significantly increased agalactosylation and decreased digalactosylation and sialylation, consistent with a pro-inflammatory IgG glycosylation profile. The non-germinal center B-cell-like (non-GCB) subtype showed significantly lower monogalactosylation than germinal center B-cell like (GCB) DLBCL. Across multiple established prognostic indices, increasing clinical risk was consistently associated with increased agalactosylation and reduced digalactosylation. During follow-up, 20 patients (37%) relapsed, and 21 (39%) died. Increased agalactosylation was independently associated with shorter PFS, whereas reduced sialylation predicted both inferior PFS and an increased risk of relapse. Conclusions: Plasma IgG N-glycosylation is profoundly altered in DLBCL, NOS and is associated with molecular subtype, established prognostic indices, and clinically relevant outcomes. These findings identify plasma IgG N-glycosylation as a promising minimally invasive biomarker that reflects disease biology and provides prognostic information beyond conventional clinical risk models. Given the exploratory nature and modest size of this cohort, these findings should be considered hypothesis-generating and require validation in larger prospective cohorts.
- Open Access
Longitudinal Changes in IgG N-glycome Are Associated with Disease Severity and Mortality in COVID-19 Patients
Severe COVID-19 is characterized by immune dysregulation, yet reliable biomarkers associated with adverse outcomes remain limited. Immunoglobulin G (IgG) N-glycosylation modulates antibody effector function and reflects the immune system’s inflammatory state. In this study, we investigated whether specific IgG glycosylation profiles are associated with COVID-19 severity, mortality, and clinical course in patients without known prior SARS-CoV-2 infection. Of the 806 admitted COVID-19 patients included in the study, 377 hospitalized patients were longitudinally monitored, and 2001 serum samples were analyzed. Significant alterations in IgG N-glycome composition were observed in patients with severe disease and those who died. The most prominent changes included increased agalactosylation and decreased mono- and digalactosylation, features associated with a more pro-inflammatory IgG glycosylation profile. Nosocomial infections were associated with a more pro-inflammatory IgG glycosylation profile. No statistically significant differences in IgG N-glycome composition were observed between vaccinated and unvaccinated patients, although the small number of vaccinated patients limited this analysis. The observed glycomic profiles likely reflect immune responses characteristic of the early phase of the COVID-19 pandemic. Whether similar glycosylation changes occur in other infectious or inflammatory diseases remains to be established. IgG glycosylation analysis holds promise for personalized risk stratification and early therapeutic intervention in COVID-19 and other severe infectious diseases.
Open AccessLongitudinal Changes in IgG N-glycome Are Associated with Disease Severity and Mortality in COVID-19 Patients
Severe COVID-19 is characterized by immune dysregulation, yet reliable biomarkers associated with adverse outcomes remain limited. Immunoglobulin G (IgG) N-glycosylation modulates antibody effector function and reflects the immune system’s inflammatory state. In this study, we investigated whether specific IgG glycosylation profiles are associated with COVID-19 severity, mortality, and clinical course in patients without known prior SARS-CoV-2 infection. Of the 806 admitted COVID-19 patients included in the study, 377 hospitalized patients were longitudinally monitored, and 2001 serum samples were analyzed. Significant alterations in IgG N-glycome composition were observed in patients with severe disease and those who died. The most prominent changes included increased agalactosylation and decreased mono- and digalactosylation, features associated with a more pro-inflammatory IgG glycosylation profile. Nosocomial infections were associated with a more pro-inflammatory IgG glycosylation profile. No statistically significant differences in IgG N-glycome composition were observed between vaccinated and unvaccinated patients, although the small number of vaccinated patients limited this analysis. The observed glycomic profiles likely reflect immune responses characteristic of the early phase of the COVID-19 pandemic. Whether similar glycosylation changes occur in other infectious or inflammatory diseases remains to be established. IgG glycosylation analysis holds promise for personalized risk stratification and early therapeutic intervention in COVID-19 and other severe infectious diseases.
- Open Access
Impact of Antidiabetic Medications on IgG and Plasma Protein N-Glycosylation in Type 2 Diabetes Patients
Introduction: Diabetes is a growing global health challenge, necessitating effective management strategies. Glycosylation, a highly regulated post-translational protein modification, has emerged as a pivotal factor in diabetes pathophysiology. However, the modulation of protein glycosylation by antidiabetic treatment is still largely unknown. This study explored the longitudinal effects of four distinct antidiabetic therapies – metformin, insulin, sodium-glucose cotransporter-2 (SGLT2) inhibitors, and glucagon-like peptide-1 receptor agonists (GLP-1RA) – on plasma protein and immunoglobulin G (IgG) glycosylation in patients with type 2 diabetes (T2D). Research Design and Methods: Plasma protein and IgG N-glycans were enzymatically released, purified and chromatographically profiled in a cohort of 124 patients, examined at four time points, to assess therapy-induced glycan alterations. Linear mixed models adjusting for covariates and multiple testing (FDR<0.05) were used to investigate the associations between plasma protein and IgG N-glycosylation and antidiabetic therapy. Results: Our findings reveal that metformin, SGLT2 inhibitors, and GLP-1RA induce significant alterations in IgG glycosylation, including the increased core fucosylation and galactosylation, features associated with a reduced inflammatory IgG potential. Notably, IgG monogalactosylation, previously linked to cardioprotective effects in women, was elevated in response to GLP-1RA and SGLT2 inhibitor treatments. Plasma protein glycosylation changes were more limited, with distinct alterations observed for each therapy. Metformin and GLP-1RA similarly reduced certain fucosylated and sialylated glycans, while SGLT2 inhibitors decreased a high-mannose glycan, previously positively associated with diabetes progression. Insulin therapy had a minimal effect on protein glycosylation, with only one plasma glycan significantly altered. Conclusions: Our findings emphasise the importance of protein glycosylation as a dynamic and responsive marker in T2D treatment. The distinct glycan alterations observed in response to metformin, SGLT2 inhibitors, and GLP-1 receptor agonists provide novel insights into the molecular effects of these therapies, potentially contributing to the development of glycan-based biomarkers for personalized diabetes management. What is already known on this topic?: ✓ Protein glycosylation is known to regulate multiple processes related to glucose homeostasis. ✓ Previous studies have shown that the IgG and plasma protein N-glycome (the entire set of N-glycans covalently attached to the IgG and plasma proteins, respectively) can help identify individuals at increased cardiometabolic risk. ✓ Despite most T2D patients receiving antidiabetic treatment, research on its effects on protein glycosylation remains scarce. What this study adds?: ✓ It is the first study to explore the effects of SGLT2 inhibitor and GLP-1RA therapy on protein glycosylation. ✓ The cardioprotective effects of these drug classes were also reflected in IgG glycosylation, demonstrated by increased monogalactosylation. ✓ Metformin, SGLT2 inhibitors, and GLP-1RA induce significant increase in IgG core fucosylation, a feature associated with reduced inflammatory IgG potential, possibly suggesting a shared pathway in suppressing inflammatory response. How this study might affect research, practice or policy?: ✓ The observed alterations in protein glycosylation across different therapeutic groups highlight its dynamic nature in response to metabolic interventions. ✓ Given the role of glycans in modulating immune function and inflammation, these findings suggest that glycan alterations could serve as potential biomarkers for assessing therapeutic response and disease progression in T2D. ✓ Future studies involving protein glycosylation should account for the potential confounding effects of antidiabetic medications to ensure accurate interpretations.
Open AccessImpact of Antidiabetic Medications on IgG and Plasma Protein N-Glycosylation in Type 2 Diabetes Patients
Introduction: Diabetes is a growing global health challenge, necessitating effective management strategies. Glycosylation, a highly regulated post-translational protein modification, has emerged as a pivotal factor in diabetes pathophysiology. However, the modulation of protein glycosylation by antidiabetic treatment is still largely unknown. This study explored the longitudinal effects of four distinct antidiabetic therapies – metformin, insulin, sodium-glucose cotransporter-2 (SGLT2) inhibitors, and glucagon-like peptide-1 receptor agonists (GLP-1RA) – on plasma protein and immunoglobulin G (IgG) glycosylation in patients with type 2 diabetes (T2D). Research Design and Methods: Plasma protein and IgG N-glycans were enzymatically released, purified and chromatographically profiled in a cohort of 124 patients, examined at four time points, to assess therapy-induced glycan alterations. Linear mixed models adjusting for covariates and multiple testing (FDR<0.05) were used to investigate the associations between plasma protein and IgG N-glycosylation and antidiabetic therapy. Results: Our findings reveal that metformin, SGLT2 inhibitors, and GLP-1RA induce significant alterations in IgG glycosylation, including the increased core fucosylation and galactosylation, features associated with a reduced inflammatory IgG potential. Notably, IgG monogalactosylation, previously linked to cardioprotective effects in women, was elevated in response to GLP-1RA and SGLT2 inhibitor treatments. Plasma protein glycosylation changes were more limited, with distinct alterations observed for each therapy. Metformin and GLP-1RA similarly reduced certain fucosylated and sialylated glycans, while SGLT2 inhibitors decreased a high-mannose glycan, previously positively associated with diabetes progression. Insulin therapy had a minimal effect on protein glycosylation, with only one plasma glycan significantly altered. Conclusions: Our findings emphasise the importance of protein glycosylation as a dynamic and responsive marker in T2D treatment. The distinct glycan alterations observed in response to metformin, SGLT2 inhibitors, and GLP-1 receptor agonists provide novel insights into the molecular effects of these therapies, potentially contributing to the development of glycan-based biomarkers for personalized diabetes management. What is already known on this topic?: ✓ Protein glycosylation is known to regulate multiple processes related to glucose homeostasis. ✓ Previous studies have shown that the IgG and plasma protein N-glycome (the entire set of N-glycans covalently attached to the IgG and plasma proteins, respectively) can help identify individuals at increased cardiometabolic risk. ✓ Despite most T2D patients receiving antidiabetic treatment, research on its effects on protein glycosylation remains scarce. What this study adds?: ✓ It is the first study to explore the effects of SGLT2 inhibitor and GLP-1RA therapy on protein glycosylation. ✓ The cardioprotective effects of these drug classes were also reflected in IgG glycosylation, demonstrated by increased monogalactosylation. ✓ Metformin, SGLT2 inhibitors, and GLP-1RA induce significant increase in IgG core fucosylation, a feature associated with reduced inflammatory IgG potential, possibly suggesting a shared pathway in suppressing inflammatory response. How this study might affect research, practice or policy?: ✓ The observed alterations in protein glycosylation across different therapeutic groups highlight its dynamic nature in response to metabolic interventions. ✓ Given the role of glycans in modulating immune function and inflammation, these findings suggest that glycan alterations could serve as potential biomarkers for assessing therapeutic response and disease progression in T2D. ✓ Future studies involving protein glycosylation should account for the potential confounding effects of antidiabetic medications to ensure accurate interpretations.
- Open Access
- 23 April 2026
- Published by Springer Nature in Research Square
The Immunoglobulin G Glycome: A Modifiable Biomarker and Functional Effector of Aging, Disease, and Mortality
Glycosylation is a key structural modification of immunoglobulin G (IgG) that modulates its effector functions and has multiple roles in balancing inflammation. Altered IgG glycosylation has been reported in many diseases, often years before clinical manifestation, suggesting its causal role and biomarker potential. Here, we analyzed IgG glycome composition in 20,405 individuals from 42 different studies processed at the Genos Glycoscience Research Laboratory between 2008 and 2025. Across nearly all diseases, specific IgG glycome profiles reflected accelerated biological aging. Accelerated glycan aging was strongly associated with increased risk of all-cause mortality, independent of established clinical risk factors and potential confounders. Moreover, interventions known to reduce mortality risk, including hormone replacement therapy, therapeutic plasma exchange and caloric restriction, were associated with reversal of glycan aging. Given their role in modulating low-grade systemic inflammation, IgG glycans may represent a functional link between chronic inflammation, aging, disease susceptibility and all-cause mortality.
- 23 April 2026
- Published by Springer Nature in Research Square
Open AccessThe Immunoglobulin G Glycome: A Modifiable Biomarker and Functional Effector of Aging, Disease, and Mortality
Glycosylation is a key structural modification of immunoglobulin G (IgG) that modulates its effector functions and has multiple roles in balancing inflammation. Altered IgG glycosylation has been reported in many diseases, often years before clinical manifestation, suggesting its causal role and biomarker potential. Here, we analyzed IgG glycome composition in 20,405 individuals from 42 different studies processed at the Genos Glycoscience Research Laboratory between 2008 and 2025. Across nearly all diseases, specific IgG glycome profiles reflected accelerated biological aging. Accelerated glycan aging was strongly associated with increased risk of all-cause mortality, independent of established clinical risk factors and potential confounders. Moreover, interventions known to reduce mortality risk, including hormone replacement therapy, therapeutic plasma exchange and caloric restriction, were associated with reversal of glycan aging. Given their role in modulating low-grade systemic inflammation, IgG glycans may represent a functional link between chronic inflammation, aging, disease susceptibility and all-cause mortality.
- Open Access
- 1 July 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-17
A genome-wide association study in 10,000 individuals links plasma N-glycome to liver disease and anti-inflammatory proteins
More than a half of plasma proteins are N-glycosylated. Most of them are synthesized, glycosylated, and secreted to the bloodstream by liver and lymphoid tissues. While associations with N-glycosylation are implicated in the rising number of liver, cardiometabolic, and immune diseases, little is known about the genetic regulation of this process. Here, we performed the largest genome-wide association study of N-glycosylation of the blood plasma proteome in 10,000 individuals. We doubled the number of genetic loci known to be associated with blood N-glycosylation by identifying 16 novel loci and prioritizing 13 novel genes contributing to N-glycosylation. Among these were the GCKR, TRIB1, HP, SERPINA1 and CFH genes. These genes are predominantly expressed in the liver and show a previously unknown genetic link between plasma protein N-glycosylation, metabolic and liver diseases, and inflammatory response. By integrating glycomics, proteomics, transcriptomics, and genomics, we provide a resource that facilitates deeper exploration of disease pathogenesis and supports the discovery of glycan-based biomarkers.
- 1 July 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-17
Open AccessA genome-wide association study in 10,000 individuals links plasma N-glycome to liver disease and anti-inflammatory proteins
More than a half of plasma proteins are N-glycosylated. Most of them are synthesized, glycosylated, and secreted to the bloodstream by liver and lymphoid tissues. While associations with N-glycosylation are implicated in the rising number of liver, cardiometabolic, and immune diseases, little is known about the genetic regulation of this process. Here, we performed the largest genome-wide association study of N-glycosylation of the blood plasma proteome in 10,000 individuals. We doubled the number of genetic loci known to be associated with blood N-glycosylation by identifying 16 novel loci and prioritizing 13 novel genes contributing to N-glycosylation. Among these were the GCKR, TRIB1, HP, SERPINA1 and CFH genes. These genes are predominantly expressed in the liver and show a previously unknown genetic link between plasma protein N-glycosylation, metabolic and liver diseases, and inflammatory response. By integrating glycomics, proteomics, transcriptomics, and genomics, we provide a resource that facilitates deeper exploration of disease pathogenesis and supports the discovery of glycan-based biomarkers.
- Open Access
A genome-wide association study in 10,000 individuals links plasma N-glycome to liver disease and anti-inflammatory proteins
More than a half of plasma proteins are N-glycosylated. Most of them are synthesized, glycosylated, and secreted to the bloodstream by liver and lymphoid tissues. While associations with N-glycosylation are implicated in the rising number of liver, cardiometabolic, and immune diseases, little is known about the genetic regulation of this process. Here, we performed the largest genome-wide association study of N-glycosylation of the blood plasma proteome in 10,000 individuals. We doubled the number of genetic loci known to be associated with blood N-glycosylation by identifying 16 novel loci and prioritizing 13 novel genes contributing to N-glycosylation. Among these were the GCKR , TRIB1 , HP, SERPINA1 and CFH genes. These genes are predominantly expressed in the liver and show a previously unknown genetic link between plasma protein N-glycosylation, metabolic and liver diseases, and inflammatory response. By integrating glycomics, proteomics, transcriptomics, and genomics, we provide a resource that facilitates deeper exploration of disease pathogenesis and supports the discovery of glycan-based biomarkers.
Open AccessA genome-wide association study in 10,000 individuals links plasma N-glycome to liver disease and anti-inflammatory proteins
More than a half of plasma proteins are N-glycosylated. Most of them are synthesized, glycosylated, and secreted to the bloodstream by liver and lymphoid tissues. While associations with N-glycosylation are implicated in the rising number of liver, cardiometabolic, and immune diseases, little is known about the genetic regulation of this process. Here, we performed the largest genome-wide association study of N-glycosylation of the blood plasma proteome in 10,000 individuals. We doubled the number of genetic loci known to be associated with blood N-glycosylation by identifying 16 novel loci and prioritizing 13 novel genes contributing to N-glycosylation. Among these were the GCKR , TRIB1 , HP, SERPINA1 and CFH genes. These genes are predominantly expressed in the liver and show a previously unknown genetic link between plasma protein N-glycosylation, metabolic and liver diseases, and inflammatory response. By integrating glycomics, proteomics, transcriptomics, and genomics, we provide a resource that facilitates deeper exploration of disease pathogenesis and supports the discovery of glycan-based biomarkers.
- 9 April 2024
- Published by Oxford University Press (OUP) in Glycobiology
- Vol. 34 (6)
Variability of human Alpha-1-acid glycoprotein N-glycome in a Caucasian population
Aim: Alpha-1-acid glycoprotein (AGP) is a highly glycosylated protein in human plasma and one of the most abundant acute phase proteins in humans. Glycosylation plays a crucial role in its biological functions, and alterations in AGP N-glycome have been associated with various diseases and inflammatory conditions. However, large-scale studies of AGP N-glycosylation in the general population are lacking. Methods: Using recently developed high-throughput glycoproteomic workflow for site-specific AGP N-glycosylation analysis, 803 individuals from the Croatian island of Korcula were analyzed and their AGP N-glycome data associated with biochemical and physiological traits, as well as different environmental factors. Results: After regression analysis, we found that AGP N-glycosylation is strongly associated with sex, somewhat less with age, along with multiple biochemical and physiological traits (e.g. BMI, triglycerides, uric acid, glucose, smoking status, fibrinogen). Conclusion: For the first time we have extensively explored the inter-individual variability of AGP N-glycome in a general human population, demonstrating its changes with sex, age, biochemical, and physiological status of individuals, providing the baseline for future population and clinical studies.
- 9 April 2024
- Published by Oxford University Press (OUP) in Glycobiology
- Vol. 34 (6)
Variability of human Alpha-1-acid glycoprotein N-glycome in a Caucasian population
Aim: Alpha-1-acid glycoprotein (AGP) is a highly glycosylated protein in human plasma and one of the most abundant acute phase proteins in humans. Glycosylation plays a crucial role in its biological functions, and alterations in AGP N-glycome have been associated with various diseases and inflammatory conditions. However, large-scale studies of AGP N-glycosylation in the general population are lacking. Methods: Using recently developed high-throughput glycoproteomic workflow for site-specific AGP N-glycosylation analysis, 803 individuals from the Croatian island of Korcula were analyzed and their AGP N-glycome data associated with biochemical and physiological traits, as well as different environmental factors. Results: After regression analysis, we found that AGP N-glycosylation is strongly associated with sex, somewhat less with age, along with multiple biochemical and physiological traits (e.g. BMI, triglycerides, uric acid, glucose, smoking status, fibrinogen). Conclusion: For the first time we have extensively explored the inter-individual variability of AGP N-glycome in a general human population, demonstrating its changes with sex, age, biochemical, and physiological status of individuals, providing the baseline for future population and clinical studies.
- Open Access
- 1 February 2024
- Published by MDPI AG in Antibodies
- Vol. 13 (1) , 9
Anastrozole and Tamoxifen Impact on IgG Glycome Composition Dynamics in Luminal A and Luminal B Breast Cancers
This study examines the intricate relationship between protein glycosylation dynamics and therapeutic responses in Luminal A and Luminal B breast cancer subtypes, focusing on anastrozole and tamoxifen impacts. The present methods inadequately monitor and forecast patient reactions to these treatments, leaving individuals vulnerable to the potential adverse effects of these medications. This research investigated glycan structural changes by following patients for up to 9 months. The protocol involved a series of automated steps including IgG isolation, protein denaturation, glycan labelling, purification, and final analysis using capillary gel electrophoresis with laser-induced fluorescence. The results suggested the significant role of glycan modifications in breast cancer progression, revealing distinctive trends in how anastrozole and tamoxifen elicit varied responses. The findings indicate anastrozole’s association with reduced sialylation and increased core fucosylation, while tamoxifen correlated with increased sialylation and decreased core fucosylation. These observations suggest potential immunomodulatory effects: anastrozole possibly reducing inflammation and tamoxifen impacting immune-mediated cytotoxicity. This study strongly emphasizes the importance of considering specific glycan traits to comprehend the dynamic mechanisms driving breast cancer progression and the effects of targeted therapies. The nuanced differences observed in glycan modifications between these two treatments underscore the necessity for further comprehensive research aimed at thoroughly evaluating the long-term implications and therapeutic efficacy for breast cancer patients.
- 1 February 2024
- Published by MDPI AG in Antibodies
- Vol. 13 (1) , 9
Open AccessAnastrozole and Tamoxifen Impact on IgG Glycome Composition Dynamics in Luminal A and Luminal B Breast Cancers
This study examines the intricate relationship between protein glycosylation dynamics and therapeutic responses in Luminal A and Luminal B breast cancer subtypes, focusing on anastrozole and tamoxifen impacts. The present methods inadequately monitor and forecast patient reactions to these treatments, leaving individuals vulnerable to the potential adverse effects of these medications. This research investigated glycan structural changes by following patients for up to 9 months. The protocol involved a series of automated steps including IgG isolation, protein denaturation, glycan labelling, purification, and final analysis using capillary gel electrophoresis with laser-induced fluorescence. The results suggested the significant role of glycan modifications in breast cancer progression, revealing distinctive trends in how anastrozole and tamoxifen elicit varied responses. The findings indicate anastrozole’s association with reduced sialylation and increased core fucosylation, while tamoxifen correlated with increased sialylation and decreased core fucosylation. These observations suggest potential immunomodulatory effects: anastrozole possibly reducing inflammation and tamoxifen impacting immune-mediated cytotoxicity. This study strongly emphasizes the importance of considering specific glycan traits to comprehend the dynamic mechanisms driving breast cancer progression and the effects of targeted therapies. The nuanced differences observed in glycan modifications between these two treatments underscore the necessity for further comprehensive research aimed at thoroughly evaluating the long-term implications and therapeutic efficacy for breast cancer patients.
- Open Access
- 8 December 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 9 (49) , eadg2615
Human-specific features and developmental dynamics of the brain N-glycome
Comparative “omics” studies have revealed unique aspects of human neurobiology, yet an evolutionary perspective of the brain N-glycome is lacking. We performed multiregional characterization of rat, macaque, chimpanzee, and human brain N-glycomes using chromatography and mass spectrometry and then integrated these data with complementary glycotranscriptomic data. We found that, in primates, the brain N-glycome has diverged more rapidly than the underlying transcriptomic framework, providing a means for rapidly generating additional interspecies diversity. Our data suggest that brain N-glycome evolution in hominids has been characterized by an overall increase in complexity coupled with a shift toward increased usage of α(2-6)–linked N -acetylneuraminic acid. Moreover, interspecies differences in the cell type expression pattern of key glycogenes were identified, including some human-specific differences, which may underpin this evolutionary divergence. Last, by comparing the prenatal and adult human brain N-glycomes, we uncovered region-specific neurodevelopmental pathways that lead to distinct spatial N-glycosylation profiles in the mature brain.
- 8 December 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 9 (49) , eadg2615
Open AccessHuman-specific features and developmental dynamics of the brain N-glycome
Comparative “omics” studies have revealed unique aspects of human neurobiology, yet an evolutionary perspective of the brain N-glycome is lacking. We performed multiregional characterization of rat, macaque, chimpanzee, and human brain N-glycomes using chromatography and mass spectrometry and then integrated these data with complementary glycotranscriptomic data. We found that, in primates, the brain N-glycome has diverged more rapidly than the underlying transcriptomic framework, providing a means for rapidly generating additional interspecies diversity. Our data suggest that brain N-glycome evolution in hominids has been characterized by an overall increase in complexity coupled with a shift toward increased usage of α(2-6)–linked N -acetylneuraminic acid. Moreover, interspecies differences in the cell type expression pattern of key glycogenes were identified, including some human-specific differences, which may underpin this evolutionary divergence. Last, by comparing the prenatal and adult human brain N-glycomes, we uncovered region-specific neurodevelopmental pathways that lead to distinct spatial N-glycosylation profiles in the mature brain.
- Open Access
Effects of testosterone and metformin on the GlycanAge index of biological age and the composition of the IgG glycome
With aging, there is a correlation between a decline in the body’s ability to maintain regular functioning and greater susceptibility to age-related diseases. Therapeutic interventions targeting the underlying biological changes of aging hold promise for preventing or delaying multiple age-related diseases. Metformin, a drug commonly used for diabetes treatment, has emerged as a potential gerotherapeutic agent due to its established safety record and preclinical and clinical data on its anti-aging effects. Glycosylation, one of the most common and complex co- and post-translational protein modifications, plays a crucial role in regulating protein function and has been linked to aging and various diseases. Changes in IgG glycosylation patterns have been observed with age, and these alterations may serve as valuable biomarkers for disease predisposition, diagnosis, treatment monitoring, and overall health assessment. In this study, we analyzed the IgG glycosylation patterns of individuals under treatment with metformin, testosterone, metformin plus testosterone and placebo, and investigated the longitudinal changes in glycosylation over time. We observed statistically significant differences in the IgG glycome composition between participants on testosterone therapy and placebo, with decreased agalactosylation and increased galactosylation and sialylation. However, metformin therapy did not result in statistically significant changes in glycosylation patterns. These findings contribute to our understanding of the impact of therapeutic interventions on IgG glycosylation and confirm the value of IgG glycosylation as a significant biomarker, capable of assessing biological age using the GlycanAge index and providing insight into overall health compared to chronological age.
Open AccessEffects of testosterone and metformin on the GlycanAge index of biological age and the composition of the IgG glycome
With aging, there is a correlation between a decline in the body’s ability to maintain regular functioning and greater susceptibility to age-related diseases. Therapeutic interventions targeting the underlying biological changes of aging hold promise for preventing or delaying multiple age-related diseases. Metformin, a drug commonly used for diabetes treatment, has emerged as a potential gerotherapeutic agent due to its established safety record and preclinical and clinical data on its anti-aging effects. Glycosylation, one of the most common and complex co- and post-translational protein modifications, plays a crucial role in regulating protein function and has been linked to aging and various diseases. Changes in IgG glycosylation patterns have been observed with age, and these alterations may serve as valuable biomarkers for disease predisposition, diagnosis, treatment monitoring, and overall health assessment. In this study, we analyzed the IgG glycosylation patterns of individuals under treatment with metformin, testosterone, metformin plus testosterone and placebo, and investigated the longitudinal changes in glycosylation over time. We observed statistically significant differences in the IgG glycome composition between participants on testosterone therapy and placebo, with decreased agalactosylation and increased galactosylation and sialylation. However, metformin therapy did not result in statistically significant changes in glycosylation patterns. These findings contribute to our understanding of the impact of therapeutic interventions on IgG glycosylation and confirm the value of IgG glycosylation as a significant biomarker, capable of assessing biological age using the GlycanAge index and providing insight into overall health compared to chronological age.